Neurocrine Biosciences, Inc. announced new data from the Phase 3 CAHtalyst Adult and Pediatric studies of CRENESSITY. The data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia (CAH) achieved physiologic-range glucocorticoid (GC) doses and normal androstenedione (A4) levels.
Additionally, adult male patients with classic CAH observed improvements in select reproductive hormone levels, including luteinizing hormone (LH) and A4-to-testosterone ratio (A4/T). Both adult and pediatric patients achieved substantial reductions in GC doses, with 47% of male patients normalizing LH levels and 19% normalizing A4/T at Week 24.
These results were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting. CRENESSITY, a novel oral corticotropin-releasing factor type 1 receptor antagonist, has demonstrated the potential to achieve two key therapeutic goals: reducing the effects of excess androgens and enabling reduction in GC doses, which may help reduce adverse effects associated with chronic high-dose GC exposure.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.